Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

por Klünder, Ben, Mohamed, Mohamed-Eslam F., Othman, Ahmed A.
Publicado 2017

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication

por Mohamed, Mohamed-Eslam F., Klünder, Ben, Othman, Ahmed A.
Publicado 2019

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

por Mohamed, Mohamed‐Eslam F., Klünder, Ben, Camp, Heidi S., Othman, Ahmed A.
Publicado 2019

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

por Mohamed, Mohamed‐Eslam F., Beck, Denise, Camp, Heidi S., Othman, Ahmed A.
Publicado 2019

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation

por Mohamed, Mohamed‐Eslam F., Klünder, Ben, Lacerda, Ana P., Othman, Ahmed A.
Publicado 2019

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

por Mohamed, Mohamed‐Eslam F., Gopalakrishnan, Sathej, Teixeira, Henrique D., Othman, Ahmed A.
Publicado 2020

Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity

por Mohamed, Mohamed‐Eslam F., Zeng, Jiewei, Jiang, Ping, Hosmane, Balakrishna, Othman, Ahmed A.
Publicado 2017

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects

por Mohamed, Mohamed‐Eslam F., Trueman, Sheryl, Feng, Tian, Friedman, Alan, Othman, Ahmed A.
Publicado 2018

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

por Muensterman, Elena, Engelhardt, Benjamin, Gopalakrishnan, Sathej, Anderson, Jaclyn K., Mohamed, Mohamed‐Eslam F.
Publicado 2021

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

por Mohamed, Mohamed‐Eslam F., Zeng, Jiewei, Marroum, Patrick J., Song, In‐Ho, Othman, Ahmed A.
Publicado 2018

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail

por Mohamed, Mohamed‐Eslam F., Feng, Tian, Enejosa, Jeffrey V., Fisniku, Ogert, Othman, Ahmed A.
Publicado 2019

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects

por Mohamed, Mohamed‐Eslam F., Coppola, Sheryl, Feng, Tian, Camp, Heidi S., Kim, Elaine, Othman, Ahmed A.
Publicado 2021

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics

por Mohamed, Mohamed‐Eslam F., Trueman, Sheryl, Feng, Tian, Anderson, Jaclyn, Marbury, Thomas C., Othman, Ahmed A.
Publicado 2019

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Ph...

por Klünder, Ben, Mittapalli, Rajendar K., Mohamed, Mohamed-Eslam F., Friedel, Anna, Noertersheuser, Peter, Othman, Ahmed A.
Publicado 2019

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics

por Trueman, Sheryl, Mohamed, Mohamed‐Eslam F., Feng, Tian, Lacerda, Ana Paula, Marbury, Thomas, Othman, Ahmed A.
Publicado 2019

Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients

por Ponce-Bobadilla, Ana Victoria, Stodtmann, Sven, Eckert, Doerthe, Zhou, Wen, Liu, Wei, Mohamed, Mohamed-Eslam F.
Publicado 2022

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinet...

por Othman, Ahmed A., Chatamra, Krai, Mohamed, Mohamed-Eslam F., Dutta, Sandeep, Benesh, Janet, Yanagawa, Masayoshi, Nagai, Masahiro
Publicado 2015

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation

por Mohamed, Mohamed-Eslam F., Trueman, Sheryl, Othman, Ahmed A., Han, Jian-Hwa, Ju, Tzuchi R., Marroum, Patrick
Publicado 2019

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate

por Mohamed, Mohamed‐Eslam F., Minocha, Mukul, Trueman, Sheryl, Feng, Tian, Enejosa, Jeffrey, Fisniku, Ogert, Othman, Ahmed A.
Publicado 2020

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis

por Nader, Ahmed, Mohamed, Mohamed‐Eslam F., Winzenborg, Insa, Doelger, Eva, Noertersheuser, Peter, Pangan, Aileen L., Othman, Ahmed A.
Publicado 2019